SynthesisCancer immunology, immunotherapy : CII2022

Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials.

Thierry Landre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.